The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

EDITORIAL

TAVR in younger patients with aortic stenosis: anything new?

EuroIntervention 2018;14:29-30. DOI: 10.4244/EIJV14I1A4

1. Baylor Scott & White Health, Dallas, TX, USA; 2. The Heart Hospital Baylor Plano Research Center, Plano, TX, USA


Transcatheter aortic valve replacement (TAVR) has been shown to be non-inferior to surgical aortic valve replacement (SAVR) in multiple randomised trials in high- and intermediate-risk patients1-5. Most patients studied in these randomised trials were elderly, being for the most part in their late seventies and early eighties in age. Two trials in lower-risk patients which have recently completed enrolment in the USA presumably include younger patients. However, the results of those trials will not be available until mid 2019.

In this issue of EuroIntervention, Eggebrecht and colleagues have attempted to shed some light on the outcomes of TAVR ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
CTO PCI, the evolution of the revolution: time for consensus on definitions